Tirzepatide started as a weight loss drug. The 2024 to 2026 trial readouts suggest it is also one of the most effective drugs ever tested for heart failure with preserved ejection fraction and for the metabolic liver disease formerly called NASH. Here is what SUMMIT and SYNERGY-NASH actually showed.
🔑 Key Takeaways
- Tirzepatide is a dual GLP-1 and GIP receptor agonist, not a pure GLP-1 like semaglutide. The dual mechanism is the proposed reason for its broader cardiac and hepatic effects.
- The SUMMIT trial (731 patients with HFpEF + obesity) showed a 38% reduction in cardiovascular death or worsening heart failure events on tirzepatide vs placebo over 104 weeks. Hospitalizations for heart failure dropped 56%.
- The SYNERGY-NASH trial (Phase 2b, 196 patients with biopsy-proven MASH and stage 2 to 3 fibrosis) showed 62% MASH resolution on tirzepatide 15 mg vs 10% on placebo at 52 weeks. About 51% achieved at least one fibrosis stage improvement.
- FDA approval status as of April 2026: Tirzepatide is approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). HFpEF approval has been submitted to FDA and EMA. MASH is investigational pending Phase 3.
- The benefit is not just from weight loss. Mechanistic substudies show reduced paracardiac fat, lower CRP, improved vascular function, reduced liver fat through AMPK and lipid metabolism pathways. Two patients losing the same amount of weight differ on these markers.
- Tirzepatide is HFpEF-specific in the cardiac data. There is no equivalent randomized trial in HFrEF (reduced ejection fraction). Mechanistically the drug should still help, but the evidence is HFpEF only.
- Off-label use in HFpEF and MASH is increasingly common ahead of formal approvals. The drug is the same molecule as approved Mounjaro/Zepbound; the indication change is regulatory, not pharmacologic.
- Side effect profile is the standard GLP-1 picture (GI symptoms in titration, gallstone risk with rapid weight loss). The HF population tolerates tirzepatide as well as the obesity population in SUMMIT.
This page covers the two emerging tirzepatide indications most actively researched in 2024 to 2026: heart failure with preserved ejection fraction (HFpEF) per the SUMMIT trial, and metabolic dysfunction-associated steatohepatitis (MASH) per the SYNERGY-NASH trial.
The SUMMIT Trial: Tirzepatide for HFpEF + Obesity
The trial that changed how cardiologists think about heart failure with preserved ejection fraction.
HFpEF was, until recently, the heart failure type with no good drug options. SGLT2 inhibitors (empagliflozin, dapagliflozin) helped. ARNI (sacubitril/valsartan) helped less than in HFrEF. Beta-blockers and ACE inhibitors did almost nothing in HFpEF specifically. The SUMMIT trial put tirzepatide on the same shelf as the SGLT2s, with arguably stronger effect sizes.
| SUMMIT trial detail | Value |
|---|---|
| Population | 731 patients with HFpEF + obesity (BMI ≥30) |
| Median age | 65 years |
| Female | 53% |
| Median BMI | 38 kg/m² |
| Treatment duration | 104 weeks (median) |
| Tirzepatide dose | Up to 15 mg weekly (titrated) |
| Primary endpoint | Composite of CV death or worsening HF event |
| Result | 9.9% (tirzepatide) vs 15.3% (placebo); HR 0.62; p=0.026; 38% relative risk reduction |
| HF hospitalization reduction | 56% |
| Body weight reduction | -13.9% (tir) vs -2.2% (placebo) |
| KCCQ-CSS at 52 weeks | +19.5 points (tir) vs +12.7 (placebo) — quality of life |
| Six-minute walk distance | +26.0m (tir) vs +10.1m (placebo) — functional capacity |
| GI events leading to discontinuation | 6.3% (tir) vs 1.4% (placebo) |
| Lead investigator | Milton Packer, MD (Baylor University) |
| Presented | AHA Scientific Sessions, November 16, 2024 |
| Published | NEJM |
Why HFpEF specifically
HFpEF is largely a disease of metabolic dysfunction. Most HFpEF patients are obese, have insulin resistance, have hypertension, have visceral adiposity, and have elevated paracardiac (around-the-heart) fat. The pathology is metabolic at root. A drug that fixes the metabolic root is, in retrospect, exactly what HFpEF needed.
HFrEF is a different disease. The heart muscle itself fails. The drugs that work in HFrEF (beta-blockers, ARNI, MRA, SGLT2) target the failing pump. Tirzepatide has not been tested in a randomized trial in HFrEF, so its benefit in that population remains unproven, even though mechanism would suggest some effect.
The mechanism beyond weight loss
SUMMIT included a CMR (cardiac MRI) substudy. The findings:
- Reduced paracardiac adipose tissue volume
- Reduced left ventricular mass (hypertrophy regression)
- Lower systemic inflammation (CRP)
- Improved vascular function via NO-related pathways
- Reduced blood pressure independent of weight loss
- Improved cardiac substrate utilization
These are the mechanistic fingerprints of a drug that does more than shrink fat. Two patients losing the same amount of weight differ on these measures, which is the basis for the "beyond weight loss" framing of the trial.
The SYNERGY-NASH Trial: Tirzepatide for MASH and Fibrosis
The most effective MASH drug data ever published.
MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) is the inflammatory advanced stage of fatty liver disease. About 5% of U.S. adults have MASH. The previous standard of care was lifestyle modification, with very limited drug options (resmetirom received FDA approval in 2024 with modest efficacy). Tirzepatide's SYNERGY-NASH numbers blow past any prior MASH drug.
| SYNERGY-NASH detail | Value |
|---|---|
| Population | 196 adults with biopsy-proven MASH and F2/F3 fibrosis |
| Age range | 18 to 80 years |
| Trial design | Phase 2b, double-blind, randomized, placebo-controlled |
| Treatment duration | 52 weeks |
| Doses | 5 mg, 10 mg, 15 mg weekly subcutaneous |
| Primary endpoint | MASH resolution without fibrosis worsening |
Primary endpoint: MASH resolution
| Dose | MASH resolution | vs placebo (10%) |
|---|---|---|
| 5 mg | 44% | +34 percentage points |
| 10 mg | 56% | +46 percentage points |
| 15 mg | 62% | +52 percentage points |
Secondary endpoint: fibrosis improvement
At least one fibrosis stage improvement without MASH worsening:
- 5 mg: 55%
- 10 mg: 51%
- 15 mg: 51%
- Placebo: 30%
The fibrosis benefit was relatively dose-flat (5 mg matched 15 mg), suggesting that even moderate doses produce most of the structural liver improvement, and the MASH resolution effect tracks more closely with the higher doses.
Body weight reduction at 52 weeks
- 5 mg: -10.7%
- 10 mg: -13.3%
- 15 mg: -15.6%
- Placebo: -0.8%
Liver fat data from related trials
The SURPASS-3 MRI substudy in diabetics on tirzepatide showed a 47.1% relative reduction in liver fat content at 15 mg vs 11.2% with insulin degludec. The structural change in the liver is happening fast.
The mechanism for the liver
The hepatic effects work through several pathways:
- AMPK activation (improves fatty acid oxidation)
- NF-κB suppression (reduces inflammation)
- Reduced CD36 expression (lower fatty acid uptake into hepatocytes)
- Reduced de novo lipogenesis
- Improved insulin sensitivity at hepatocytes
- Reduced visceral adiposity (less portal-vein lipid flux)
Tirzepatide vs Other GLP-1s for HF and Liver Disease
| Drug | HFpEF data | MASH data | Status |
|---|---|---|---|
| Tirzepatide (Mounjaro/Zepbound) | SUMMIT: 38% RR reduction | SYNERGY-NASH Phase 2b: 62% MASH resolution at 15 mg | FDA: pending HFpEF; investigational MASH |
| Semaglutide | STEP-HFpEF: ~75% reduction in HF hospitalization, smaller cohort | ESSENCE: ~63% MASH resolution at 2.4 mg, fibrosis improvement smaller than SYNERGY | FDA: not approved for HFpEF or MASH |
| Liraglutide | Limited HF data | LEAN trial: ~39% MASH resolution | Older agent, limited use for these indications |
| Survodutide | No HF trial | Phase 2 MASH: ~83% MASH resolution at 6 mg (small Phase 2) | Investigational |
| Retatrutide | No HF trial | Phase 2 MASH: substantial effect, results emerging | Investigational |
Off-Label Tirzepatide for HF and MASH (Pre-Approval)
The drug is approved for diabetes and obesity. It is widely prescribed off-label for HFpEF and MASH ahead of formal indication.
What that means in practice
- The molecule is the same. Mounjaro for diabetes, Zepbound for obesity, off-label tirzepatide for HFpEF or MASH are all the same drug.
- Insurance coverage for off-label use is variable. Cardiologists and hepatologists may need to write letters of medical necessity.
- Coverage codes that work: type 2 diabetes (universal), obesity (BMI 30+ or 27+ with comorbidity), now HFpEF + obesity is increasingly accepted ahead of formal approval.
- Compounded tirzepatide is widely used by telehealth providers, with FDA pressure increasing on compounding pharmacies as of 2025 to 2026.
Who is a candidate
- HFpEF + obesity (BMI ≥30): The exact SUMMIT population. Strongest off-label evidence.
- HFpEF without obesity: Mechanism plausible, no trial data. Use is more cautious.
- MASH + obesity: Strongest off-label MASH case.
- MASH without obesity: Use is increasing as the underlying mechanism (visceral fat, insulin resistance) often applies even at lower BMI.
- HFrEF: No randomized trial. Off-label use is rare and contested.
Side Effects and Tolerability in HF and Liver Populations
SUMMIT and SYNERGY-NASH found tolerability comparable to obesity trials. The standard GLP-1 GI profile applies (nausea, diarrhea, constipation, decreased appetite). Most are mild to moderate and resolve with titration.
Population-specific concerns:
- HF patients: Watch for dehydration from GI symptoms. Diuretic dose may need adjustment as weight drops.
- MASH patients: Lipase monitoring at baseline is reasonable since some MASH patients have subclinical pancreatic dysfunction. Slower titration tolerated better.
- Both populations: Gallstone risk is real with rapid weight loss; the rate doubles vs diabetes-indication use.
Frequently Asked Questions
Medical disclaimer. This article is informational only and does not replace individualized medical advice. Tirzepatide use in heart failure and MASH is, as of April 2026, off-label for these specific indications in the United States. Decisions about prescribing tirzepatide for HFpEF or MASH should be made with the prescribing clinician, ideally with input from a cardiologist or hepatologist as the case warrants.